SCHEMBL16669705

SCHEMBL16669705

Cc1ccc2nc(-c3cc4ccc(N5CC[C@H](NC(=O)O)C5)cc4oc3=O)cn2c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 15/20 0.43
NPC1 O15118 3/20 0.41
ALDH1A1 P00352 3/20 0.41
RAB9A P51151 3/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
ESR1 P03372 1/20 0.41
TP53 P04637 1/20 0.41
CASP1 P29466 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PKM P14618 1/20 0.39
SLC16A3 O15427 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16669595 0.92 SUV39H2 (0.43) SUV39H2NPC1ALDH1A1RAB9AMAPT
SCHEMBL15086168 0.90 SUV39H2 (0.54) SUV39H2
SCHEMBL15069006 0.83 SUV39H2 (0.48) SUV39H2NPC1ALDH1A1RAB9AMAPT
SCHEMBL16674755 0.82 SUV39H2 (0.56) SUV39H2
SCHEMBL15069158 0.81 NPC1 (0.44) SUV39H2NPC1ALDH1A1RAB9AMAPT
SCHEMBL15066195 0.80 NPC1 (0.41) SUV39H2NPC1ALDH1A1RAB9AMAPT
SCHEMBL15068439 0.80 NPC1 (0.46) NPC1ALDH1A1RAB9AMAPTLMNA
SCHEMBL15069070 0.80 NPC1 (0.47) SUV39H2NPC1ALDH1A1RAB9AMAPT
SCHEMBL15067136 0.80 NPC1 (0.47) SUV39H2NPC1ALDH1A1RAB9AMAPT
SCHEMBL15068850 0.78 NPC1 (0.46) NPC1ALDH1A1RAB9AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US claimed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US claimed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US claimed
EP-2797592-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2019-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 SUV39H2 708/4885NPC1 4329/4885ALDH1A1 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.